JP2008522957A - エトフェナマート含有外用貼付剤 - Google Patents
エトフェナマート含有外用貼付剤 Download PDFInfo
- Publication number
- JP2008522957A JP2008522957A JP2007529287A JP2007529287A JP2008522957A JP 2008522957 A JP2008522957 A JP 2008522957A JP 2007529287 A JP2007529287 A JP 2007529287A JP 2007529287 A JP2007529287 A JP 2007529287A JP 2008522957 A JP2008522957 A JP 2008522957A
- Authority
- JP
- Japan
- Prior art keywords
- patch
- weight
- sensitive adhesive
- pressure
- etofenamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229960001493 etofenamate Drugs 0.000 title claims abstract description 24
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 18
- 229920005989 resin Polymers 0.000 claims abstract description 14
- 239000011347 resin Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 13
- 229920003051 synthetic elastomer Polymers 0.000 claims abstract description 13
- 239000005061 synthetic rubber Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 239000010410 layer Substances 0.000 claims abstract description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 9
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical group C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 9
- 229960003338 crotamiton Drugs 0.000 claims description 9
- 239000004014 plasticizer Substances 0.000 claims description 8
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 7
- 239000013032 Hydrocarbon resin Substances 0.000 claims description 3
- 125000002723 alicyclic group Chemical group 0.000 claims description 3
- 229920006270 hydrocarbon resin Polymers 0.000 claims description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 231100000245 skin permeability Toxicity 0.000 abstract description 13
- 230000007794 irritation Effects 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 description 21
- 230000001070 adhesive effect Effects 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- -1 liquid paraffin Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 5
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 5
- 229920002799 BoPET Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002759 woven fabric Substances 0.000 description 3
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920003049 isoprene rubber Polymers 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007718 adhesive strength test Methods 0.000 description 1
- 229920006271 aliphatic hydrocarbon resin Polymers 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000010690 paraffinic oil Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
即ち、本発明は支持体上に粘着基剤及び薬物を含有する粘着剤層が積層された貼付剤であって、該粘着基剤が合成ゴム系高分子5〜50重量%、粘着付与樹脂10〜60重量%、流動パラフィン25〜60重量%を基剤成分とし、薬物としてエトフェナマートを配合してなる外用貼付剤に関する。
粘着付与樹脂の配合量は、10〜60重量%、好ましくは15〜50重量%、更に好ましくは20〜40重量%である。10重量%未満では、貼付剤の粘着力が極端に低下し、また60重量%を超えると粘着力が強くなりすぎ、皮膚から剥がすとき、物理的な皮膚刺激を生じ、また、粘着剤の粘度が高くなりすぎる。
流動パラフィンの配合量は、本発明の製剤において極めて重要な役割を持つ。
流動パラフィンの配合量は、25〜60重量%、好ましくは25〜50重量%、更に好ましくは30〜40重量%である。25重量%未満では粘着力が強くなりすぎ、皮膚から剥がすとき、物理的な皮膚刺激を生じる。更に薬剤の皮膚透過性が極端に減少する(図1参照)。60重量%を超えると十分な粘着力が得られず、更に粘着剤の凝集力が低下し、従って皮膚に粘着剤残りが生じる可能性がある。
本発明に使用される可塑剤として、トリアセチン、クロタミトン、脂肪酸エステル類(セバシン酸ジエチル、クエン酸トリエチル、ミリスチン酸イソプロピル等)、N-メチルピロリドン等があげられる。
可塑剤の配合量は、通常0.5〜20重量%、好ましくは1〜10重量%、更に好ましくは3〜7重量%である。可塑剤は1種または2種以上組合せて用いてもよい。本発明に使用される可塑剤として、クロタミトンとミリスチン酸イソプロピルの組合せが特に好ましい。
クロタミトンの配合量は、0.5〜5重量%が好ましい。0.5重量%未満では、その効果が低減され、5重量%を超えると粘着剤の凝集破壊が生じ、剥離時、皮膚に粘着剤残りが生じる。ミリスチン酸イソプロピルの配合量は、0.5〜15重量%が好ましい。0.5重量%未満では、その効果が低減され、15重量%を超えると粘着剤の凝集破壊が生じ、剥離時、皮膚に粘着剤残りが生じる。クロタミトンとミリスチン酸イソプロピルを組合せる時の配合比は1:1〜1:3が好ましい。
抗酸化剤としては、ジブチルヒドロキシトルエン及びその誘導体、トコフェロール、及びその誘導体、アスコルビン酸及びその誘導体などがあげられる。充填剤としては炭酸カルシウム、炭酸マグネシウム、硫酸マグネシウム、酸化亜鉛、酸化チタン、ケイ酸類またはその塩(二酸化ケイ素、ケイ酸アルミニウム、ケイ酸マグネシウム、軽質無水ケイ酸等)等が用いられる。防腐剤としてはパラベン類(パラオキシ安息香酸エステル類)等が用いられる。軟化剤としては、石油系オイル(パラフィン系油、芳香族系油等)、シリコン油、液状ゴム(ボリブテン、液状イソプレンゴム等)、高級脂肪酸類、高級脂肪酸エステル類、多価アルコール(ポリエチレングリコール、プロピレングリコール、ジエチレングリコール、シクロプロピレングリコール、グリセリン、サリチル酸グリコール等)、植物油(オリーブ油、ユーカリ油)等が挙げられる。
即ち、合成ゴム系高分子、粘着付与樹脂、流動パラフィン、軟化剤、抗酸化剤及び充填剤等を加熱溶解した後、冷却して粘着剤温度を下げ、エトフェナマート、必要に応じて可塑剤を添加し、攪拌錬合する。得られた膏体をシリコン処理したPETフィルム上に塗工した後、支持体としてポリエステル製織布をラミネートし、適当な大きさに切断して、本発明の経皮吸収製剤を得ることができる。
エトフェナマートの皮膚透過性を検討するため、実施例1、2、3、4、5及び比較例1、2、3、4、5の各製剤を用いて、ラットでの皮膚透過性試験(in vitro)を行った。除毛したラット腹部摘出皮膚をフランツ型拡散セルにセットし、その内側にはレセプター液としてリン酸緩衝生理食塩水を満たし、セルの外部のウオータージャケットには37℃の温水を還流した。各製剤は直径2.5cmに打ち抜き、セル上のラット摘出皮膚に貼付し、経時的にレセプター液をサンプリングし、液体クロマトグラフィーにより、エトフェナマートの透過量を測定した。
結果を図−1に示した。アクリル系貼付剤より合成ゴム系貼付剤の方がエトフェナマートの皮膚透過性が高く、更に合成ゴム系貼付剤に流動パラフィンを25%以上含有させることによりエトフェナマートの皮膚透過性が上昇し、クロタミトン及びミリスチン酸イソプロピルの添加により更に上昇した。
実施例2、実施例3、実施例4、実施例5、比較例1及び比較例2の各製剤を3cm×4cmに切断し、カラゲニン投与の4時間前に右後肢足蹠に貼付した。1%カラゲニン生理食塩液0.1mLをラットの右後肢足蹠に皮下投与し、足蹠浮腫を惹起させ、投与前と投与後4時間の足容積を測定した。以下に示す計算式に従い浮腫率の抑制率を算出した。
計算式:
浮腫率(%)={(惹起4時間後の足容積(mL)−惹起前の足容積(mL))/惹起前の足容積(mL)}×100
抑制率(%)={1−試験製剤の浮腫率(%)/未処置群の浮腫率(%)}×100
結果を表−1に示した。本試験に用いた実施例すべてについて浮腫抑制効果があり、特にクロタミトン及びミリスチン酸イソプロピルを添加した製剤においてはコントロール製剤に対して統計学的に有意な浮腫抑制効果(Student’s t-test,p<0.01)が示された。
JIS Z0237 14:傾斜式ボールタック法に準拠して各製剤の粘着力を測定した。実施例1、実施例2、実施例5、比較例1、比較例2及び比較例5の各製剤を10cm×5cmに切断した。測定装置の傾斜角は30度、傾斜板はアクリル板、助走路及び測定部は10cmとした。測定は各製剤につき3回ずつ行い、測定部に5秒以上停止したボール中で最大のボールナンバーを測定値とした。
結果を表−2に示した。アクリル系貼付剤より合成ゴム系貼付剤の方が粘着力が高く、更に流動パラフィンを25%以上含有させることにより粘着力がより改善された。
日本白色雌性ウサギ8匹を用いて試験を行った。ウサギの背部被毛を除毛後、1匹当たり左右2ヶ所ずつ、計4ヶ所を貼付部位とした。右側2ヶ所を健常部位とし、左2ヶ所を損傷部位とした。損傷部位は注射針で#型に損傷させた。直径2.5cmに打ち抜いたコントロール、実施例2、実施例5、比較例1、比較例2及び比較例5の各製剤(n=6)を貼付し、絆創膏で固定後、更に保護衣を装着して貼付剤の移動を防止した。貼付24時間後に各貼付剤を取り除き、その後1時間、24時間及び48時間目に皮膚反応を観察した。
その結果を表−4に示した。本試験に用いた実施例ではすべて低刺激性であった。
Claims (5)
- 支持体上に粘着基剤及び薬物を含有する粘着剤層が積層された貼付剤であって、該粘着基剤が合成ゴム系高分子5〜50重量%、粘着付与樹脂10〜60重量%、流動パラフィン25〜60重量%を基剤成分とし、薬物としてエトフェナマートを配合してなる外用貼付剤。
- 合成ゴム系高分子がスチレン-イソプレン-スチレンブロック共重合体である請求項1に記載の外用貼付剤。
- 粘着付与樹脂が脂環族飽和炭化水素樹脂である請求項1に記載の外用貼付剤。
- 粘着剤層中に更に可塑剤を含有する請求項1〜3のうちいずれか一項に記載の外用貼付剤。
- 可塑剤がクロタミトン又はミリスチン酸イソプロピルである請求項4に記載の外用貼付剤。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/019143 WO2006064576A1 (en) | 2004-12-15 | 2004-12-15 | External patches containing etofenamate |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008522957A true JP2008522957A (ja) | 2008-07-03 |
JP5043664B2 JP5043664B2 (ja) | 2012-10-10 |
Family
ID=34959649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007529287A Active JP5043664B2 (ja) | 2004-12-15 | 2004-12-15 | エトフェナマート含有外用貼付剤 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8747885B2 (ja) |
EP (1) | EP1833471B1 (ja) |
JP (1) | JP5043664B2 (ja) |
KR (1) | KR101304702B1 (ja) |
CN (1) | CN101080219B (ja) |
AU (1) | AU2004325626B2 (ja) |
CA (1) | CA2588732C (ja) |
ES (1) | ES2536478T3 (ja) |
HK (1) | HK1108119A1 (ja) |
NO (1) | NO338478B1 (ja) |
WO (1) | WO2006064576A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011083787A1 (ja) * | 2010-01-07 | 2011-07-14 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
WO2019124261A1 (ja) * | 2017-12-19 | 2019-06-27 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004325626B2 (en) * | 2004-12-15 | 2010-12-09 | Drossapharm Ag | External patches containing etofenamate |
DK2120896T3 (en) * | 2007-01-11 | 2017-09-11 | Drossapharm Ag | MEDICAL ACTIVE PLASTER |
CN101925355B (zh) | 2008-01-28 | 2013-05-29 | 帝国制药株式会社 | 含芬太尼的外用贴剂 |
NZ596398A (en) * | 2009-07-24 | 2013-08-30 | Teikoku Seiyaku Kk | Fentanyl-containing adhesive preparation for external use |
KR101900519B1 (ko) * | 2010-11-02 | 2018-09-19 | 데이고꾸세이약꾸가부시끼가이샤 | 펠비낙 함유 외용 첩부제 |
JP5698018B2 (ja) * | 2011-02-02 | 2015-04-08 | 日東電工株式会社 | 貼付剤および貼付製剤 |
CN107684552B (zh) * | 2016-12-12 | 2020-06-23 | 安徽天耘医疗器械有限公司 | 一种依托芬那酯贴剂 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455146A (en) * | 1979-04-03 | 1984-06-19 | Hisamitsu Pharmaceutical Co., Ltd. | Novel plasters |
JPS60139615A (ja) * | 1983-12-10 | 1985-07-24 | バイエル・アクチエンゲゼルシャフト | 活性化合物開放系 |
JPS60158110A (ja) * | 1983-12-28 | 1985-08-19 | バイエル・アクチエンゲゼルシヤフト | 活性化合物放出系 |
JPS60204715A (ja) * | 1984-03-13 | 1985-10-16 | バイエル・アクチエンゲゼルシヤフト | 薬剤硬膏及びその製造方法 |
JPS63246327A (ja) * | 1987-04-02 | 1988-10-13 | Teikoku Seiyaku Kk | エトフエナマ−ト含有貼付薬 |
JPH07215850A (ja) * | 1994-02-04 | 1995-08-15 | Sekisui Chem Co Ltd | 局所麻酔用経皮吸収テープ |
JPH09291028A (ja) * | 1996-04-26 | 1997-11-11 | Sekisui Chem Co Ltd | 貼付剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5867617A (ja) * | 1981-10-17 | 1983-04-22 | Nitto Electric Ind Co Ltd | 消炎鎮痛貼付剤 |
GB2256135B (en) * | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
JP3086290B2 (ja) * | 1991-07-26 | 2000-09-11 | エスエス製薬株式会社 | ジクロフェナクナトリウム貼付剤 |
JPH1045569A (ja) | 1996-04-26 | 1998-02-17 | Sekisui Chem Co Ltd | 貼付剤 |
US6620430B2 (en) * | 1996-12-06 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Plaster containing felbinac |
DE19804604A1 (de) | 1998-02-06 | 1999-08-12 | Beiersdorf Ag | Vorrichtung zur Freigabe von Stoffen |
GB0018467D0 (en) * | 2000-07-27 | 2000-09-13 | Strakan Pharm Ltd | Adhesives |
ATE553756T1 (de) * | 2000-11-29 | 2012-05-15 | Teikoku Seiyaku Kk | Adhäsive zubereitung zur externen anwendung |
DE10137405A1 (de) | 2001-07-31 | 2003-02-20 | Beiersdorf Ag | Verfahren zur kontinuierlichen Herstellung und Beschichtung von Selbstklebemassen auf Basis von SBC mit mindestens einem pharmazeutischen Wirkstoff |
AU2004325626B2 (en) * | 2004-12-15 | 2010-12-09 | Drossapharm Ag | External patches containing etofenamate |
EP1854456B1 (en) * | 2005-02-28 | 2017-08-23 | Hisamitsu Pharmaceutical Co., Inc. | Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base |
-
2004
- 2004-12-15 AU AU2004325626A patent/AU2004325626B2/en active Active
- 2004-12-15 WO PCT/JP2004/019143 patent/WO2006064576A1/en active Application Filing
- 2004-12-15 ES ES04807500.6T patent/ES2536478T3/es active Active
- 2004-12-15 EP EP04807500.6A patent/EP1833471B1/en active Active
- 2004-12-15 CN CN2004800446159A patent/CN101080219B/zh active Active
- 2004-12-15 US US11/793,231 patent/US8747885B2/en active Active
- 2004-12-15 CA CA2588732A patent/CA2588732C/en active Active
- 2004-12-15 JP JP2007529287A patent/JP5043664B2/ja active Active
- 2004-12-15 KR KR1020077015789A patent/KR101304702B1/ko active IP Right Grant
-
2007
- 2007-07-13 NO NO20073627A patent/NO338478B1/no unknown
-
2008
- 2008-02-22 HK HK08101962.4A patent/HK1108119A1/xx unknown
-
2014
- 2014-04-29 US US14/264,238 patent/US20140234396A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4455146A (en) * | 1979-04-03 | 1984-06-19 | Hisamitsu Pharmaceutical Co., Ltd. | Novel plasters |
JPS60139615A (ja) * | 1983-12-10 | 1985-07-24 | バイエル・アクチエンゲゼルシャフト | 活性化合物開放系 |
JPS60158110A (ja) * | 1983-12-28 | 1985-08-19 | バイエル・アクチエンゲゼルシヤフト | 活性化合物放出系 |
JPS60204715A (ja) * | 1984-03-13 | 1985-10-16 | バイエル・アクチエンゲゼルシヤフト | 薬剤硬膏及びその製造方法 |
JPS63246327A (ja) * | 1987-04-02 | 1988-10-13 | Teikoku Seiyaku Kk | エトフエナマ−ト含有貼付薬 |
JPH07215850A (ja) * | 1994-02-04 | 1995-08-15 | Sekisui Chem Co Ltd | 局所麻酔用経皮吸収テープ |
JPH09291028A (ja) * | 1996-04-26 | 1997-11-11 | Sekisui Chem Co Ltd | 貼付剤 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011083787A1 (ja) * | 2010-01-07 | 2011-07-14 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
US8657798B2 (en) | 2010-01-07 | 2014-02-25 | Teikoku Seiyaku Co., Ltd. | Anti-inflammatory analgesic adhesive patch for external use |
JP5748671B2 (ja) * | 2010-01-07 | 2015-07-15 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
WO2019124261A1 (ja) * | 2017-12-19 | 2019-06-27 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
JPWO2019124261A1 (ja) * | 2017-12-19 | 2020-11-19 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
US11607394B2 (en) | 2017-12-19 | 2023-03-21 | Hisamitsu Pharmaceutical Co., Inc. | Rotigotine-containing patch |
Also Published As
Publication number | Publication date |
---|---|
HK1108119A1 (en) | 2008-05-02 |
US20140234396A1 (en) | 2014-08-21 |
EP1833471A1 (en) | 2007-09-19 |
ES2536478T3 (es) | 2015-05-25 |
AU2004325626A1 (en) | 2006-06-22 |
US8747885B2 (en) | 2014-06-10 |
EP1833471B1 (en) | 2015-03-25 |
CA2588732C (en) | 2012-09-11 |
NO20073627L (no) | 2007-07-13 |
CN101080219A (zh) | 2007-11-28 |
JP5043664B2 (ja) | 2012-10-10 |
CN101080219B (zh) | 2010-11-17 |
WO2006064576A1 (en) | 2006-06-22 |
US20080089926A1 (en) | 2008-04-17 |
AU2004325626B2 (en) | 2010-12-09 |
KR101304702B1 (ko) | 2013-09-06 |
NO338478B1 (no) | 2016-08-22 |
KR20070089224A (ko) | 2007-08-30 |
CA2588732A1 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Subedi et al. | Recent advances in transdermal drug delivery | |
KR100846642B1 (ko) | 첩부제 | |
JP4873871B2 (ja) | 粘着剤及び貼付剤 | |
TW201119691A (en) | Donepazil-containing percutaneous absorption type preparation | |
JP2003137773A (ja) | 積層支持体を有する貼付剤 | |
WO2005102393A1 (ja) | 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤 | |
WO2007099966A1 (ja) | 経皮吸収型製剤 | |
US20140234396A1 (en) | External patches containing etofenamate | |
JP4986411B2 (ja) | 貼付剤 | |
KR20110036709A (ko) | 경피 흡수 촉진제 및 이를 사용한 경피 투여 제제 | |
JP6872675B1 (ja) | ロチゴチン含有貼付剤 | |
JP3066515B2 (ja) | 尿失禁治療用経皮投与製剤 | |
JP5181320B2 (ja) | 皮膚刺激の少ない経皮吸収型製剤 | |
CA2783964C (en) | Piroxicam-containing transdermally absorbable preparation | |
CN104173322A (zh) | 一种含吡罗昔康的经皮吸收制剂及其制备方法 | |
WO2009096354A1 (ja) | フェンタニル含有外用貼付剤 | |
JP3199770B2 (ja) | 経皮投与用貼付剤及びその製造法 | |
JP5564241B2 (ja) | フェルビナク含有経皮吸収製剤 | |
JP6963663B2 (ja) | 貼付剤の製造方法 | |
JPH01297069A (ja) | 粘着剤組成物 | |
JP5856975B2 (ja) | フェルビナク含有外用貼付剤 | |
JPH085806B2 (ja) | 経皮吸収製剤 | |
JP2016196426A (ja) | フェンタニル含有貼付剤 | |
JP2019034905A (ja) | デヒドロ酢酸含有経皮吸収製剤 | |
WO2021024105A1 (en) | Tulobuterol transdermal patch and it's process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110823 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120314 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120521 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120619 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120712 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5043664 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150720 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |